WASHINGTON, April 9, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that its proprietary antibody-drug conjugate (ADC), labetuzumab-SN-38, appears to be safe and reasonably well tolerated within a clinically effective dosage range in patients with advanced colorectal cancer. Results from this Phase I study were presented by Dr. Neil H. Segal from the Memorial Sloan Kettering Cancer Center, New York, NY.
Immunomedics Reports First Results Of Labetuzumab-SN-38 In Colorectal Cancer
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts